ReviewInternational journal for parasitology. Drugs and drug resistance2012
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
Review in International journal for parasitology. Drugs and drug resistance, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nutritional supplements for patients being treated for active visceral leishmaniasis.The Cochrane database of systematic reviews · 2018Pooled it
- Visceral leishmaniasis: an integrated review of resistance mechanisms, host immunometabolism, and next generation therapeutics.Inflammopharmacology · 2026Review
- In vitro anti-Trypanosomatid activity and chemical profile of crude extracts of Chromolaena hookeriana and Campuloclinium macrocephalum (Asteraceae).Memorias do Instituto Oswaldo Cruz · 2026Article
- Advances and challenges in the search for new treatments for Chagas disease.Memorias do Instituto Oswaldo Cruz · 2026Review
- Identification of novel inhibitors from3 Biotech · 2025Article
- Clinical Profiles and Outcomes of rK39-Confirmed Paediatric Visceral Leishmaniasis at a General Hospital in Massawa, Eritrea: A Retrospective Study.International journal of general medicine · 2025Article
- Molecular docking ofIn silico pharmacology · 2025Article
- Disease foci of pharmaceutical research and development as reflected in applications for International Nonproprietary Names, 1953-2022.Bulletin of the World Health Organization · 2025Article
- Novel Diacyl-hydrazide Compounds as Potential Therapeutics for Visceral Leishmaniasis.ACS omega · 2024Article
- Effect of the aggregated protein dye YAT2150 onAntimicrobial agents and chemotherapy · 2024Article
- TargetingFrontiers in pharmacology · 2024Article
- Epidemiology, clinical characteristics, and treatment outcomes of leishmaniasis in Qatar: A retrospective study.Qatar medical journal · 2024Article
- Design, synthesis, electrochemistry and anti-trypanosomatid hit/lead identification of nitrofuranylazines.RSC medicinal chemistry · 2023Article
- Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host.Pathogens (Basel, Switzerland) · 2023Review
- Advances in Protozoan Epigenetic Targets and Their Inhibitors for the Development of New Potential Drugs.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Constituents of the Stem Bark ofMolecules (Basel, Switzerland) · 2023Article
- Development of a multi-epitope vaccine candidate for leishmanial parasites applying immunoinformatics andFrontiers in immunology · 2023Article
- Leishmanicidal and immunomodulatory properties of Brazilian green propolis extract (EPP-AFFrontiers in pharmacology · 2023Article
- Canine Leishmaniasis: Update on Epidemiology, Diagnosis, Treatment, and Prevention.Veterinary sciences · 2022Review
- Effects of Structurally Different HDAC Inhibitors againstACS infectious diseases · 2022Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their limitations. We also discuss the new strategies in the drug discovery field including the development and implementation of high-throughput screening (HTS) assays and the joint efforts of international teams to deliver clinical candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.